AMED Fair Value Estimate
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Amedisys Inc
Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is inpatient hospital, palliative, and skilled nursing facility (“SNF”) care in their homes; home-based recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. Nearly 3,000 hospitals and more than 110,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 19,000 employees in 521 care centers in 37 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of nearly 470,000 patients in need every year, performing more than 10.6 million visits annually.
Net income compounded at -15.6% annually over 6 years.
Current Price
$100.99
+0.01%GoodMoat Value
$205.64
103.6% undervaluedBlended fair value estimate based on DCF, Graham Number, and earnings-based models.
Graham Number, PEG-based, and Earnings-based models
View Fair Value →Amedisys Inc (AMED) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The GoodMoat Fair Value target for Amedisys Inc is $205.64. The current stock price is $100.99, suggesting the stock is 103.6% undervalued.
The price-to-earnings (P/E) ratio is 38.71. Price-to-book ratio is 2.92. Price-to-sales ratio is 1.38. Enterprise value to EBITDA is 14.14. PEG ratio is -2.74.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Amedisys Inc's intrinsic value.